ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE and BONE DENSITY DECREASED

Overview

BONE DENSITY DECREASED is the #1 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc.. There are 4,550 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE to BONE DENSITY DECREASED. This represents approximately 10.0% of all 45,551 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE who experience bone density decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

BONE DENSITY DECREASED is moderately reported among ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE users, representing a notable but not dominant share of adverse events.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

In addition to bone density decreased, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE:

• RENAL INJURY — 3,304 reports
• SKELETAL INJURY — 3,020 reports
• CHRONIC KIDNEY DISEASE — 2,482 reports
• TOOTH LOSS — 2,455 reports
• BONE LOSS — 2,134 reports
• OSTEONECROSIS — 2,095 reports
• RENAL FAILURE — 2,052 reports
• TOOTH INJURY — 1,970 reports
• MULTIPLE FRACTURES — 1,957 reports
• PAIN — 1,843 reports

Other Drugs Associated with BONE DENSITY DECREASED

The following drugs have also been linked to bone density decreased in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE cause BONE DENSITY DECREASED?

BONE DENSITY DECREASED has been reported as an adverse event in 4,550 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is BONE DENSITY DECREASED with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

BONE DENSITY DECREASED accounts for approximately 10.0% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, making it one of the most commonly reported side effect.

What should I do if I experience BONE DENSITY DECREASED while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

If you experience bone density decreased while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages